

Company Announcement
ASX: HPC

DATE: 9 June 2023

Issue of Shares on conversion of Performance Rights

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** (“**Hydralyte North America**” or “**the Company**”) wishes to advise that it has issued 562,833 fully paid ordinary shares (“**Shares**”) on conversion of 1,111,466 unlisted performance rights (“**Performance Rights**”) issued under the Company’s Employee Share Incentive Plan (“**Plan**”) after the relevant vesting conditions were met. The Company advises that it has issued cash payments in lieu of the allocation of 548,633 Shares in accordance with the terms of the Plan.

A cleansing statement is set out below. An Appendix 2A and Appendix 3H will follow this announcement.

Cleansing Statement

The Company hereby gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Act**) that:

- a) today, 9 June 2023, the Company completed the issue and allotment of 562,833 fully paid ordinary shares (**Shares**);
- b) the Company issued the Shares without disclosure under Part 6D.2 of the Act;
- c) as at the date of this notice, the Company has complied with:
 - i) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - ii) section 674 and 674A of the Act; and
- d) as at the date of this notice there is no ‘excluded information’ (as that term is defined in section 708A(7) and (8) of the Act).

ENDS

This announcement was authorised for release by the Board of HydraLyte North America.

For further information:

Investors/Media

Henry Jordan

Six Degrees Investor Relations

0431 271 538

henry.jordan@sdir.com.au